COVID-19 Relapses, Lack Of Omicron Data Complicate Paxlovid Case In India
CHAI Hints At $25 A Course For Generic
A few cases of COVID-19 relapse have Twitter abuzz about the need for data on Paxlovid’s effectiveness, particularly against the Omicron variant and in vaccinated individuals. Despite regulatory approval in India, the drug has not yet been included in treatment guidelines and a debate on recommended dosage now complicates matters
